Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
| Status: | Completed |
|---|---|
| Conditions: | Anemia, Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any - 70 |
| Updated: | 1/20/2019 |
| Start Date: | February 1996 |
| End Date: | November 11, 2008 |
High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose
cyclophosphamide in patients with severe aplastic anemia.
II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide
shortens the time to recovery in these patients.
III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal
hemoglobinuria.
cyclophosphamide in patients with severe aplastic anemia.
II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide
shortens the time to recovery in these patients.
III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal
hemoglobinuria.
PROTOCOL OUTLINE: Patients receive high dose cyclophosphamide IV on days 1-4. Beginning on
day 10, patients receive filgrastim (G-CSF) until the absolute neutrophil count is greater
than 1,000/mm3 for 2 consecutive days.
Patients are followed every 3 months for at least 2 years and annually thereafter.
day 10, patients receive filgrastim (G-CSF) until the absolute neutrophil count is greater
than 1,000/mm3 for 2 consecutive days.
Patients are followed every 3 months for at least 2 years and annually thereafter.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Acquired severe aplastic anemia or paroxysmal nocturnal hemoglobinuria
- Not a candidate for allogeneic bone marrow transplantation
- Must meet one of the following criteria:
- Severe aplastic anemia
- Less than 25% bone marrow cellularity and depression in two of three blood
counts (reticulocytes less than 40,000/mm3
- platelet count less than 20,000/mm3 and granulocytes less than 500/mm3)
- Life-threatening paroxysmal nocturnal hemoglobinuria
- Absolute neutrophil count less than 500/mm3
- platelet transfusion dependent
- thrombotic disease
- No Fanconi anemia
- No abnormal cytogenetics
--Patient Characteristics--
- Renal: Creatinine no greater than 2.0 mg/dL
- Cardiovascular: Cardiac ejection fraction at least 45%
- Other: Not preterminal or moribund Not pregnant
We found this trial at
1
site
Click here to add this to my saved trials
